XBiotech
XBIT
46 hedge funds and large institutions have $23.2M invested in XBiotech in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 9 reducing their positions, and 12 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 9
1.7% more ownership
Funds ownership: 13.12% → 14.83% (+1.7%)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
3% more call options, than puts
Call options by funds: $30K | Put options by funds: $29K
0% more funds holding
Funds holding: 46 → 46 (0)
28% less capital invested
Capital invested by funds: $32.5M → $23.2M (-$9.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.38M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$1.91M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.81M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.13M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.36M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.38M |
| 3 |
Jane Street
New York
|
-$446K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$422K |
| 5 |
Goldman Sachs
New York
|
-$378K |
XBIT Hedge Fund Activity: Q2 2024 in Review
46 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2024, worth a combined $23.2M — down 28% from $32.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new XBIT positions and 12 closed out — a net gain of 1 holder — while 19 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $6.38M. The largest seller was Millennium Management, cutting an estimated $4.36M.
- 46 institutional investors held XBiotech (XBIT) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $23.2M of XBiotech stock for Q2 2024, down 28% quarter-over-quarter.
- 13 funds opened new XBiotech positions in Q2 2024 and 12 closed out, a net change of +1 holder.
- The largest XBiotech buyer in Q2 2024 was BlackRock, an estimated $6.38M added.
- The largest XBiotech seller in Q2 2024 was Millennium Management, an estimated $4.36M sold.
Based on aggregated 13F filings for Q2 2024.